AG
VIGL

Artal Group’s Vigil Neuroscience VIGL Stock Holding History

Artal Group’s Portfolio VIGL Stock Details VIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,828,691
Closed -$7.31M – 97
2024
Q2 		$7.31M Buy
1,828,691
+17,500
+1% +$59.9K 0.19% 49
2024
Q1 		$6.18M Hold
1,811,191
– – 0.16% 57
2023
Q4 		$6.12M Sell
1,811,191
-96,944
-5% -$499K 0.2% 45
2023
Q3 		$10.3M Sell
1,908,135
-3,056
-0.2% -$21.1K 0.44% 36
2023
Q2 		$18M Sell
1,911,191
-332,161
-15% -$3.14M 0.56% 27
2023
Q1 		$22M Hold
2,243,352
– – 1.31% 21
2022
Q4 		$28M Sell
2,243,352
-42,222
-2% -$518K 1.57% 20
2022
Q3 		$20.8M Buy
2,285,574
+1,164,383
+104% +$8.54M 0.89% 27
2022
Q2 		$2.89M Hold
1,121,191
– – 0.15% 83
2022
Q1 		$7.88M Buy
+1,121,191
New +$14.8M 0.33% 59

Other funds holding VIGL

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group's VIGL Position: Q3 2024 in Review

Artal Group sold out of Vigil Neuroscience (VIGL) in Q3 2024, closing a stake of 1,828,691 shares — an estimated $7.31M sold.

Artal Group first reported a position in VIGL in Q1 2022 and held it in 10 quarters. The position peaked at $28M in Q4 2022. 52 funds tracked by Wall St. Rank hold VIGL as of Q3 2024.

  • Artal Group reported no remaining Vigil Neuroscience position as of Q3 2024 after selling out during the quarter.
  • Artal Group sold 1,828,691 Vigil Neuroscience shares in Q3 2024, an estimated $7.31M.
  • Artal Group first reported a position in Vigil Neuroscience in Q1 2022 and held it in 10 quarters.
  • Artal Group's Vigil Neuroscience position peaked at $28M in Q4 2022.
  • 52 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.